Clinical Trial Update: Biomarker Correlates of Hypoxia in Metastatic Melanoma [Phase 2]

View source ↗

Summary

The Phase 2 trial investigating biomarker correlates of hypoxia in metastatic melanoma has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma
• Skin Cancer

Snippet

Sponsor: H. Lee Moffitt Cancer Center and Research Institute | Conditions: Melanoma, Skin Cancer | Phase 2 | Status: WITHDRAWN